Navigation Links
Onyx Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:1/4/2011

EMERYVILLE, Calif., Jan. 4, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2011 at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time).  

Interested parties may access a live webcast of the presentation on our website at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software.  For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through January 24, 2011.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
2. Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director
3. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
4. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
5. Access Pharmaceuticals Raises $6.0 Million In Registered Direct Offering
6. University of Utah and Navigen Pharmaceuticals Announce a New Government Contract to Advance Slit2N for the Treatment of Hemorrhagic Fever and Anthrax Exposure
7. Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study
8. AVANIR Pharmaceuticals Announces Proposed Public Offering of Common Stock
9. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
10. Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
11. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , ... February 23, 2017 ... ... announced today that in a published evaluation of multiple immunoassay-based threat detection ... Department of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found ...
(Date:2/23/2017)... , Feb. 23, 2017  Capricor Therapeutics, Inc. (NASDAQ: ... other medical conditions, today announced that Linda Marbán, Ph.D, president ... upcoming investor conferences: Cowen and Company ... 10:00 am ET Boston, MA ... at 9:00 am PT (12:00 pm ET) Dana ...
(Date:2/22/2017)...  Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company ... products for companion animals, will host a live conference call ... discuss financial results from the fourth quarter and full year ... investors may access the audio webcast or use ... ...
(Date:2/22/2017)... Scientists propose in Nature blocking ... Gaucher and maybe other lysosomal storage diseases as a ... current therapies. An international research team led ... also included investigators from the University of Lübeck in ... 22. The study was conducted in mouse models of ...
Breaking Biology Technology:
(Date:2/7/2017)... 7, 2017 Ipsidy Inc. ( ... [OTC: IDGS], ("Ipsidy" or the "Company") a provider of ... services, is pleased to announce the following changes as ... Effective January 31, 2017, Philip D. Beck ... and President.  An experienced payment industry professional and public ...
(Date:2/2/2017)... , Feb. 2, 2017  EyeLock LLC, a ... a new white paper " What You Should Know ... problem of ensuring user authenticity is a growing concern. ... authentication of users. However, traditional authentication schemes such as ... Biometric authentication offers an elegant solution to ...
(Date:1/26/2017)...  Crossmatch, a leading provider of security and identity ... combatting fraud, waste and abuse in assistance operations around ... on Disaster Relief conference in Panama City ... and foreign assistance organizations throughout Latin America ... a largely unacknowledged problem in the foreign assistance and ...
Breaking Biology News(10 mins):